Taro Pharmaceutical Industries Ltd. have announced that the U.S. Patent and Trademark Office has issued the company a patent for its non-sedating barbiturate drug T2007, which is currently under development.
T2007 is the sodium salt of DPB (diphenyl barbituric acid), and its use is directed to its anti-epileptic properties. In animal models, DPB has an efficacy comparable to phenobarbital, a long-established clinical treatment for epilepsy.
We view this development with interest. Taro is yet another Israel based pharmaceutical company that appears to be moving into the ethical drug development area. That said, Sun Pharmaceuticals are trying to buy up Taro, so it might end up an Indian company.